Intraocular Lymphoma: A Review

Published date: Dec 08 2025

Journal Title: Journal of Ophthalmic and Vision Research

Issue title: ‎Volume 20 - 2025

Pages: 1 - 22

DOI: 10.18502/jovr.v20.17181

Saeed Karimidr.saeedkarimi@gmail.comOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran

Kimia Daneshvarkimia_daneshvar100@yahoo.comOphthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran

Intraocular lymphoma (IOL) is a rare form of non-Hodgkin lymphoma that primarily presents in two distinct types. The first type, known as primary intraocular lymphoma (PIOL), is mainly recognized as a subtype of primary central nervous system lymphoma (PCNSL). Recent classifications have emphasized the primary ocular sites affected, with vitreoretinal lymphoma emerging as the most common variant linked to PCNSL. Despite its rarity, the incidence of PIOL is rising among both immunocompromised and immunocompetent populations. Most cases of PIOL are identified as diffuse large B-cell lymphoma, although rare T-cell variants have also been reported. Secondary intraocular lymphoma (SIOL) originates from metastatic spread of non-CNS lymphomas to the ocular structures, including the retina, uvea, vitreous body, Bruch’s membrane, and optic nerve. Diagnosis of IOL is challenging for ophthalmologists and pathologists, as it can easily mimic other ocular conditions. Advancements in laboratory diagnostics, such as immunocytochemistry, flow cytometry, and the evaluation of interleukin ratios (specifically IL-10:IL-6 > 1), along with polymerase chain reaction (PCR) amplification for clonality, have enhanced diagnostic accuracy. Multimodal imaging approaches and molecular analyses can serve as valuable indicators of visual prognosis, recurrence rates, and the likelihood of progression to central nervous system involvement. Given that misdiagnosis or delayed diagnosis can result in serious treatment delays and potentially life-threatening outcomes for patients with IOL, this review seeks to provide a comprehensive understanding of the clinical manifestations of IOL and the diagnostic methods employed.

Keywords: Intraocular Lymphoma, Masquerade Syndromes, Uveal Lymphoma, Vitreoretinal Lymphoma

1. Zhang W, Rokohl AC, Guo Y, Yao K, Fan W, Heindl LM. Global incidence and prevalence of malignant orbital tumors. Adv Ophthalmol Pract Res 2024;4:128–133.

2. He LF, Zhang JD, Chen XX, Wei RL. Epidemiology and survival outcomes of patients with primary intraocular lymphoma: A population-based analysis. BMC Ophthalmol 2022;22:486.

3. Takhar JS, Doan TA, Gonzales JA. Primary vitreoretinal lymphoma: Empowering our clinical suspicion. Curr Opin Ophthalmol 2019;30:491–499.

4. Mulay K, Narula R, Honavar SG. Primary vitreoretinal lymphoma. Indian J Ophthalmol 2015;63:180–186.

5. Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma. Ocul Immunol Inflamm 2009;17:69–72.

6. Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, et al. Primary vitreoretinal lymphoma: A report from an international primary central nervous system lymphoma collaborative group symposium. Oncologist 2011;16:1589–1599.

7. White VA. Understanding and classification of ocular lymphomas. Ocul Oncol Pathol 2019;5:379–386.

8. Levy-Clarke GA, Buggage RR, Shen D, Vaughn LO, Chan CC, Davis JL. Human T-cell lymphotropic virus type-1 associated T-cell leukemia/lymphoma masquerading as necrotizing retinal vasculitis. Ophthalmology 2002;109:1717–1722.

9. Chaput F, Amer R, Baglivo E, Touitou V, Kozyreff A, Bron D, et al. Intraocular T-cell lymphoma: Clinical presentation, diagnosis, treatment, and outcome. Ocul Immunol Inflamm 2017;25:639–648.

10. Kimura K, Usui Y, Goto H, Yoshikawa H, Sugita S, Nanba K, et al.; Japanese Intraocular Lymphoma Study Group. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol 2012;56:383–389.

11. Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med 2013;15:93–100.

12. Mercadal S, Alañá M, Barceló MI, Bruixola G, López-Pereira P, Bobillo S, et al.; Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO) and Grupo de Estudio de Neuro-Oftalmología de la Sociedad Española de Neurología (GENOSEN) group. Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain. Br J Haematol 2022;197:792–795.

13. Cho BJ, Yu HG. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma. J Neurooncol 2014;120:523–529.

14. Berenbom A, Davila RM, Lin HS, Harbour JW. Treatment outcomes for primary intraocular lymphoma: Implications for external beam radiotherapy. Eye 2007;21:1198–1201.

15. Zhao XY, Cheng TT, Meng LH, Zhang WF, Chen YX. Clinical features, diagnosis, management and prognosis of primary intraocular lymphoma. Front Oncol 2022;12:808511.

16. Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: A 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol 2013;131:50–55.

17. Sobolewska B, Chee SP, Zaguia F, Goldstein DA, Smith JR, Fend F, et al. Vitreoretinal Lymphoma. Cancers 2021;13:3921.

18. Mussatto CC, Shakoor A. Diagnosis and management of intraocular lymphoma: A narrative review. Ann Eye Sci 2022;7:28.

19. Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bülow T, et al.; Study Group for Vitreoretinal Lymphoma Diagnostics. Consensus recommendations for the diagnosis of vitreoretinal lymphoma. Ocul Immunol Inflamm 2021;29:507–520.

20. Androudi S, Apivatthakakul A, Arevalo FJ, Berkenstock MK, Carreño E, Chee SP, et al.; International Vitreoretinal B-Cell Lymphoma Registry Investigator Group. Presentation, diagnostic testing and initial treatment of vitreoretinal lymphoma. Ophthalmol Retina 2024;8:72– 80.

21. Steffen J, Coupland SE, Smith JR. Primary vitreoretinal lymphoma in HIV infection. Ocul Immunol Inflamm 2021;29:621–627.

22. Mashayekhi A, Dalvin LA, Lim LS, Ancona-Lezama D, Mazloumi M, Chang M, et al. Association of vitreoretinal lymphoma with systemic lymphoma. Retina 2021;41:259– 265.

23. Liu S, Gu J, Zhang T, Ping B, Zhou M, Huang X, et al. Clinical features, diagnostic significance, and prognosis of vitreoretinal lymphoma in young patients. Retina 2021;41:2596–2604.

24. Dutta Majumder P, Khetan V, Biswas J. Masquerade syndrome: A review of uveitic impostors. Asia Pac J Ophthalmol 2024;13:100054.

25. Kurisu N, Hiyama T, Harada Y, Fukushima N, Katsuya N, Ureshino H, et al. Vitreoretinal lymphoma in a patient with rheumatoid arthritis with a history of methotrexateassociated lymphoproliferative disorders. Ocul Immunol Inflamm 2022;32:1070–1075.

26. Zamani G, Hajipour A, Ganjeifar B, Ebrahimiadib N, Hosseini SM. Intraocular lymphoma masquerading as unilateral hypopyon anterior uveitis: A case report. J Ophthalmic Inflamm Infect 2022;12:25.

27. Evereklioglu C, Sener H, Polat OA, Horozoglu F. Comment on: Intraocular lymphoma masquerading as unilateral hypopyon anterior uveitis: A case report. J Ophthalmic Inflamm Infect 2023;13:8.

28. Nguyen NV, Khan F, Cannon A, Huang Y, Kim L, Xu R, et al. Diagnosis of primary vitreoretinal lymphoma masquerading infectious retinitis by retinal biopsy. J Ophthalmic Inflamm Infect 2024;14:8.

29. Rali A, Xu LT, Craven C, Cohen JB, Yeh S, Grossniklaus HE, et al. Diagnostic retinal biopsy in the management of secondary non-CNS vitreoretinal lymphoma masquerading as viral retinitis: A case report. Int J Retina Vitreous 2021;7:58.

30. Riazi-Esfahani H, Hassanpoor N, Ghassemi F, Zarei M. Presumed intraocular lymphoma masquerading as agerelated macular degeneration: A case report. J Curr Ophthalmol 2020;32:207–210.

31. Konda SM, Deaner JD, Proia AD, Jaffe GJ. Primary vitreoretinal lymphoma masquerading as postoperative endophthalmitis in a pregnant patient with long-standing idiopathic panuveitis. Retin Cases Brief Rep 2023;18:468– 472.

32. Fukutsu K, Namba K, Iwata D, Mizuuchi K, Kase S, Suzuki K, et al. Pseudo-inflammatory manifestations of choroidal lymphoma resembling Vogt-Koyanagi-Harada disease: Case report based on multimodal imaging. BMC Ophthalmol 2020;20:94.

33. Sonne SJ, Shieh WS, Srivastava SK, Smith BT. Lymphoma masquerading as occlusive retinal vasculitis: A case study. Am J Ophthalmol Case Rep 2020;19:100777.

34. Bawankar P, Das D, Bhattacharjee H, Tayab S, Deori N, Paulbuddhe V, et al. Systemic diffuse large Bcell lymphoma masquerading as neovascular glaucoma. Indian J Ophthalmol 2018;66:317–319.

35. Sadhar B, Yarkoni AG, Patel KK, Mantopoulos D, Milman T, Shields CL, et al. Vitreoretinal lymphoma masquerading as central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging Retina 2024;55:467–470.

36. Luo JY, Yu ST, Xu XY, Lin XX, Luo RJ, Long CD. Primary vitreoretinal lymphoma: A retrospective study of 20 eyes. J Ophthalmol 2022;2022:4522974.

37. Tekumalla S, Xu D, Awh K, Philp N, Milman T, Garg S. Diagnostic yield of in vitro vitreous biopsy for intraocular lymphoma at variable vitreous cutter speeds using 25- gauge vitrectomy. Retina 2023;43:1005–1009.

38. Kimura K, Usui Y, Goto H, Group JI; Japanese Intraocular Lymphoma Study Group. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol 2012;56:383– 389.

39. Ito T, Takeda A, Fujiwara K, Hasegawa E, Nakao S, Ohishi Y, et al. Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol 2019;257:1029–1036.

40. Lee D, Lee J, Nahm JH, Kim M. Diagnostic accuracy of vitreous cytology in patients with vitreoretinal lymphoma. J Clin Med 2022;11:6450.

41. Gonzales JA, Chan CC. Biopsy techniques and yields in diagnosing primary intraocular lymphoma. Int Ophthalmol 2007;27:241–250.

42. Kalogeropoulos D, Vartholomatos G, Mitra A, Elaraoud I, Ch’ng SW, Zikou A, et al. Primary vitreoretinal lymphoma. Saudi J Ophthalmol 2019;33:66–80.

43. Hwang CS, Yeh S, Bergstrom CS. Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how? Int Ophthalmol Clin 2014;54:155–171.

44. Mudhar HS, Sheard R. Diagnostic cellular yield is superior with full pars plana vitrectomy compared with core vitreous biopsy. Eye 2013;27:50–55.

45. Chen K, Li X, Wang D, Ma Y, Chen B, Wang Q, et al. The diagnostic value of IL-10 and IL-6 level in vitreous fluid and aqueous humor for vitreoretinal lymphoma. Clin Chim Acta 2021;515:21–26.

46. Kang H, Tao Y. Clinical utility of cytokine analysis in the diagnosis and efficacy monitoring of vitreoretinal lymphoma. Int J Ophthalmol 2022;15:1893–1902.

47. Fisson S, Ouakrim H, Touitou V, Baudet S, Ben Abdelwahed R, Donnou S, et al. Cytokine profile in human eyes: Contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. PLoS One 2013;8:e52385.

48. Frenkel S, Pe’er J, Kaufman R, Maly B, Habot-Wilner Z. The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma. Acta Ophthalmol 2020;98:e668– e673.

49. Pochat-Cotilloux C, Bienvenu J, Nguyen AM, Ohanessian R, Ghesquières H, Sève P, et al. Use of a threshold of interleukin-10 and IL-10/IL-6 ratio in ocular samples for the screening of vitreoretinal lymphoma. Retina 2018;38:773– 781.

50. Nezu N, Usui Y, Saito A, Shimizu H, Asakage M, Yamakawa N, et al. Machine learning approach for intraocular disease prediction based on aqueous humor immune mediator profiles. Ophthalmology 2021;128:1197–1208.

51. Park YG, Park WK, Kim RY, Kim M, Park YH. Serial changes in the aqueous IL-10 level after intravitreal methotrexate injection as an indicator of primary vitreoretinal lymphoma recurrence. Sci Rep 2020;10:15992.

52. Gu J, Jiang T, Liu S, Chen X, Wang Z, Zhang P, et al. Longitudinal analysis of ocular manifestation and interleukin during intravitreal treatment of vitreoretinal lymphoma with methotrexate. Am J Ophthalmol 2023;251:189–196.

53. Zhang X, Zhang Y, Zhuang Z, Zhao C, Gao F, Dai RP, et al. Cerebrospinal fluid interleukin-10 biomarker for vitreoretinal lymphoma. Am J Ophthalmol 2023;246:242– 250.

54. Santos MC, Jiang A, Li AS, Rao PK, Wilson B, Harocopos GJ. Vitreoretinal lymphoma: Optimizing diagnostic yield and accuracy. Am J Ophthalmol 2022;236:120–129.

55. Kwak JJ, Lee KS, Lee J, Kim YJ, Choi EY, Byeon SH, et al. Next-generation sequencing of vitreoretinal lymphoma by vitreous liquid biopsy: Diagnostic potential and genotype/phenotype correlation. Invest Ophthalmol Vis Sci 2023;64:27.

56. Huang RS, Mihalache A, Popovic MM, Cruz-Pimentel M, Pandya BU, Muni RH, et al. Diagnostic methods for primary vitreoretinal lymphoma: A systematic review. Surv Ophthalmol 2024;69:456–464.

57. Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol 2016;173:680–692.

58. Bonzheim I, Giese S, Deuter C, Süsskind D, Zierhut M, Waizel M, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: A valuable tool to improve diagnostic yield of vitreous aspirates. Blood 2015;126:76– 79.

59. Coupland SE, Hummel M, Müller HH, Stein H. Molecular analysis of immunoglobulin genes in primary intraocular lymphoma. Invest Ophthalmol Vis Sci 2005;46:3507– 3514.

60. Merle-Béral H, Davi F, Cassoux N, Baudet S, Colin C, Gourdet T, et al. Biological diagnosis of primary intraocular lymphoma. Br J Haematol 2004;124:469–473.

61. Wang Y, Shen D, Wang VM, Sen HN, Chan CC. Molecular biomarkers for the diagnosis of primary vitreoretinal lymphoma. Int J Mol Sci 2011;12:5684–5697.

62. Frenkel S, Pe’er J, Kaufman R, Maly B, Habot-Wilner Z. The importance of cytokines analysis in the diagnosis of vitreoretinal lymphoma. Acta Ophthalmol 2020;98:e668– e673.

63. Lee J, Kim SW, Kim H, Lee CS, Kim M, Lee SC. Differential diagnosis for vitreoretinal lymphoma with vitreoretinal findings, immunoglobulin clonality tests, and interleukin levels. Retina 2019;39:1165–1176.

64. Lee J, Kim SW, Kim H, Lee CS, Kim M, Lee SC. Differential diagnosis for vitreoretinal lymphoma with vitreoretinal findings, immunoglobulin clonality tests, and interleukin levels. Retina 2019;39:1165–1176.

65. Belhouachi N, Xochelli A, Boudjoghra M, Lesty C, Cassoux N, Fardeau C, et al. Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire. Blood Adv 2020;4:1357–1366.

66. de Hoog J, Dik WA, Lu L, Heezen KC, Ten Berge JC, Swagemakers SM, et al. Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma. Acta Ophthalmol 2019;97:626–632.

67. Miserocchi E, Ferreri AJ, Giuffrè C, Cangi MG, Francaviglia I, Calimeri T, et al. MYD88 L265P mutation detection in the aqueous humor of patients with vitreoretinal lymphoma. Retina 2019;39:679–684.

68. Raja H, Salomão DR, Viswanatha DS, Pulido JS. Prevalence of MYD88 L265P mutation in histologically proven, diffuse large B-cell vitreoretinal lymphoma. Retina 2016;36:624–628.

69. Hiemcke-Jiwa LS, Ten Dam-van Loon NH, Leguit RJ, Nierkens S, Ossewaarde-van Norel J, de Boer JH, et al. Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction. JAMA Ophthalmol 2018;136:1098–1104.

70. Wang X, Su W, Gao Y, Feng Y, Wang X, Chen X, et al. A pilot study of the use of dynamic analysis of cellfree DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas. Haematologica 2022;107:2154–2162.

71. Gu J, Jiang T, Liu S, Ping B, Li R, Chen W, et al. Cellfree DNA sequencing of intraocular fluid as liquid biopsy in the diagnosis of vitreoretinal lymphoma. Front Oncol 2022;12:932674.

72. Brown NA, Rao RC, Betz BL. Cell-free DNA extraction of vitreous and aqueous humor specimens for diagnosis and monitoring of vitreoretinal lymphoma. J Vis Exp 2024.

73. Cani AK, Hovelson DH, Demirci H, Johnson MW, Tomlins SA, Rao RC. Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: New routes to targeted therapies. Oncotarget 2017;8:7989–7998.

74. Chen K, Qin H, Li X, Zhou X, Ma J, Guan M. Diagnostic potential of vitreoretinal lymphoma by detection of gene mutations with NGS in 25 Chinese patients. Clin Chim Acta 2024;561:119827.

75. Demirci H, Rao RC, Elner VM, Demirci FY, Axenov L, Betz B, et al. Aqueous humor-derived MYD88 L265P mutation analysis in vitreoretinal lymphoma: A potential less invasive method for diagnosis and treatment response assessment. Ophthalmol Retina 2023;7:189–195.

76. Zhuang Z, Zhang Y, Zhang X, Zhang M, Zou D, Zhang L, et al. Corrigendum: Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis. Front Oncol 2023;12:1104236.

77. Zhang X, Zhang Y, Guan W, Zou D, Zhao C, Gao F, et al. Development of diagnostic recommendations for vitreoretinal lymphoma. Ocul Immunol Inflamm 2024;32:1142–1149.

78. Tanaka R, Kaburaki T, Taoka K, Karakawa A, Tsuji H, Nishikawa M, et al. More accurate diagnosis of vitreoretinal lymphoma using a combination of diagnostic test results: A prospective observational study. Ocul Immunol Inflamm 2022;30:1354–1360.

79. Bonzheim I, Salmerón-Villalobos J, Süsskind D, Szurman P, Gekeler F, Spitzer MS, et al. [Molecular diagnostics for vitreoretinal lymphoma]. Pathologie (Heidelb) 2023;44:150–154.

80. Lee J, Kim B, Lee H, Park H, Ho Byeon S, Choi JR, et al. Whole exome sequencing identifies mutational signatures of vitreoretinal lymphoma. Haematologica 2020;105:e458–e460.

81. Sobolewska B, Chee SP, Zaguia F, Goldstein DA, Smith JR, Fend F, et al. Vitreoretinal Lymphoma. Cancers 2021;13:3921.

82. Joseph D, Grover B, Telias M. Biomarker potential of vitreous microRNA in retinal disease: A metaanalysis. medRxiv [Preprint]. 2024. Available from: https://doi.org/10.1101/2024.03.25.24304858

83. Tuo J, Shen D, Yang HH, Chan CC. Distinct microRNA- 155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis. Am J Ophthalmol 2014;157:728–734.

84. Kakkassery V, Schroers R, Coupland SE, Wunderlich MI, Schargus M, Heinz C, et al. Vitreous microRNA levels as diagnostic biomarkers for vitreoretinal lymphoma. Blood 2017;129:3130–3133.

85. Minezaki T, Usui Y, Asakage M, Takanashi M, Shimizu H, Nezu N, et al. High-throughput microRNA profiling of vitreoretinal lymphoma: Vitreous and serum microRNA profiles distinct from uveitis. J Clin Med 2020;9:1–21.

86. Komatsu H, Usui Y, Yoshioka Y, Asakage M, Sugawara R, Tsubota K, et al. MicroRNA profiling in extracellular vesicles from vitreous humor and serum of patients with ocular sarcoidosis and vitreoretinal lymphoma. Invest Ophthalmol Vis Sci 2024;65:1473.

87. Kuo DE, Wei MM, Knickelbein JE, Armbrust KR, Yeung IY, Lee AY, et al. Logistic regression classification of primary vitreoretinal lymphoma versus uveitis by interleukin 6 and interleukin 10 levels. Ophthalmology 2020;127:956–962.

88. Takeda A, Yoshikawa H, Fukuhara T, Hikita S, Hijioka K, Otomo T, et al. Distinct profiles of soluble cytokine receptors between B-cell vitreoretinal lymphoma and uveitis. Invest Ophthalmol Vis Sci 2015;56:7516–7523.

89. Tian S, Chen K, Xiao J, Wang D, Zhou X, Li X, et al. APRIL and BAFF play a key role in differentiating vitreoretinal lymphoma from uveitis. Clin Chim Acta 2022;535:1–6.

90. Lavine JA, Singh AD, Sharma S, Baynes K, Lowder CY, Srivastava SK. Ultra-widefield multimodal imaging of primary vitreoretinal lymphoma. Retina 2019;39:1861–1871.

91. Lee J, Goldstein DA. The diverse multi-modal imaging findings of recurrent primary vitreoretinal lymphoma. Am J Ophthalmol Case Rep 2020;20:100936.

92. Mahdizad Z, Khalili Pour E, Mehrabi Bahar M, Esfandiari A, Masoomian B, Riazi-Esfahani H, et al. Management of primary choroidal lymphoma presenting as extensive serous retinal detachment and salmon patch of bulbar conjunctiva: A case report. J Med Case Rep 2022;16:162.

93. Wieder MS, Fleischman JA, Rashid S. Bilateral serous retinal detachments associated with Burkitt lymphoma. Am J Ophthalmol Case Rep 2020;18:100654.

94. Say EA, Knupp CL, Gertsch KR, Chavala SH. Metastatic B-cell lymphoma masquerading as infectious retinitis and vasculitis. Oncol Lett 2012;3:1245–1248.

95. Kim M, Suh H, Park YG, Park YH. Clinical features predictive of vision loss in patients with vitreoretinal lymphoma: A single tertiary center experience. Sci Rep 2023;13:4478.

96. Guan WX, Peng XY. Vitreoretinal lymphoma with intraretinal infiltration, simulating retinal necrosis. Ophthalmol Retina 2024;8:571–578.

97. Komatsu K, Sakai T, Kaburaki T, Tsuji H, Tsuneoka H. Atypical presentation of primary intraocular lymphoma. BMC Ophthalmol 2016;16:171.

98. Marchese A, Miserocchi E, Giuffrè C, Cicinelli MV, Querques G, Bandello F, et al. Aurora borealis and string of pearls in vitreoretinal lymphoma: Patterns of vitreous haze. Br J Ophthalmol 2019;103:1656–1659.

99. Zhao H, Guan W, Ma Y, Wang G, Zhang X, Xiao Y, et al. Characteristics of optical coherence tomography in patients with primary vitreoretinal lymphoma. Chinese Journal of Ocular Fundus Diseases 2021;37:133–137.

100. Zhou X, Tian S, Zhou X, Shi H, Li Y, Xiao J, et al. Optical coherence tomography benefits the diagnosis and follow-up of primary central nervous system lymphoma with intraocular involvement. Cancer Manag Res 2022;14:1007–1018.

101. Pichi F, Dolz-Marco R, Francis JH, Au A, Davis JL, Fawzi A, et al. Advanced OCT analysis of biopsy-proven vitreoretinal lymphoma. Am J Ophthalmol 2022;238:16– 26.

102. Barry RJ, Tasiopoulou A, Murray PI, Patel PJ, Sagoo MS, Denniston AK, et al. Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: A novel aid to early diagnosis. Br J Ophthalmol 2018;102:1362–1366.

103. Tropinskaya OF, Serova NK, Eliseeva NM. [Use of optical coherence tomography in diagnosis of retinal lymphomas]. Vestn Oftalmol 2022;138:14–19.

104. El Zein L, Smith WM, White LJ, Hodge DO, Olsen TW, Pulido JS, et al. Optical coherence tomography features in vitreoretinal lymphoma compared with non-infectious uveitis. BMC Ophthalmol 2024;24:255.

105. Guan W, Xiao Y, Zhao H, Hu F, Chen C, Peng X. Spectraldomain optical coherence tomography biomarkers in vitreoretinal lymphoma. Clin Exp Ophthalmol 2023;51:144–153.

106. Deák GG, Goldstein DA, Zhou M, Fawzi AA, Jampol LM. Vertical hyperreflective lesions on optical coherence tomography in vitreoretinal lymphoma. JAMA Ophthalmol 2019;137:194–198.

107. Saito T, Ohguro N, Iwahashi C, Hashida N. Optical coherence tomography manifestations of primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol 2016;254:2319–2326.

108. Yang X, Dalvin LA, Mazloumi M, Ferenczy S, Lim LS, Ancona-Lezama D, et al. Spectral domain optical coherence tomography features of vitreoretinal lymphoma in 55 eyes. Retina 2021;41:249–258.

109. Zhao H, Wang X, Mao Y, Peng X. Longitudinal observation of OCT imaging is a valuable tool to monitor primary vitreoretinal lymphoma treated with intravitreal injections of methotrexate. BMC Ophthalmol 2020;20:10.

110. Jiang T, Gu J, Liu S, Chang Q. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate. BMC Ophthalmol 2022;22:375.

111. Kim RY, Park JH, Kim M, Park YG, Cho SG, Park YH. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment. PLoS One 2021;16:e0260469.

112. Cicinelli MV, Marchese A, Miserocchi E, Giuffré C, Berchicci L, Querques G, et al. Retinal and choroidal changes of vitreoretinal lymphoma from active to remission phase after intravitreal rituximab. Ocul Immunol Inflamm 2020;28:637–646.

113. Marchese A, Cicinelli MV, Cavalleri M, Bandello F, Modorati G, Miserocchi E. Chorioretinal atrophy in vitreoretinal lymphoma: Risk factors and visual outcomes. Retina 2022;42:561–568.

114. Chen W, Gu J, Liu S, Zhao Z, Jiang T, Xu G, et al. Perivascular flower-bud-like lesions on en face optical coherence tomography angiography in patients with vitreoretinal lymphoma. Retina 2022;42:2169–2175.

115. Maggio E, Bauci F, Polito A, Arena F, Pertile G. Swept-source optical coherence tomography angiography findings in a case of primary vitreoretinal lymphoma over a three-year follow-up. BMC Ophthalmol 2024;24:194.

116. Xu Z, Bai H, Liu X, Shen J, Su Y, Wang Y. Case report: Intraretinal hyperflow microinfiltration lesions on sweptsource optical coherence tomography angiography as a potential biomarker of primary vitreoretinal lymphoma. Front Med 2024;11:1386979.

117. Pierro L, Arrigo A, Casalino G, Miserocchi E, Aragona E, Bandello F. En face optical coherence tomography angiography of primary vitreoretinal lymphoma. Ophthalmic Surg Lasers Imaging Retina 2018;49:e173– e174.

118. Casady M, Faia L, Nazemzadeh M, Nussenblatt R, Chan CC, Sen HN. Fundus autofluorescence patterns in primary intraocular lymphoma. Retina 2014;34:366–372.

119. Rishi P, Maitra P, Das K, Rishi E, Manchegowda PT. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab. Int Ophthalmol 2021;41:2711–2722.

120. Sobol EK, Abramson DH, Francis JH. Fundus autofluorescence patterns before and after treatment for primary vitreoretinal lymphoma. Invest Ophthalmol Vis Sci 2020;61:5329.

121. Ishida T, Ohno-Matsui K, Kaneko Y, Tobita H, Shimada N, Takase H, et al. Fundus autofluorescence patterns in eyes with primary intraocular lymphoma. Retina 2010;30:23– 32.

122. Mapelli C, Invernizzi A, Barteselli G, Pellegrini M, Tabacchi E, Staurenghi G, et al. Multimodal imaging of vitreoretinal lymphoma. Ophthalmologica 2016;236:166–174.

123. Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina 2002;22:37–43.

124. Alsberge JB, Johnson RN. Vitreoretinal lymphoma following primary testicular lymphoma: Report of two cases and review of the literature. Am J Ophthalmol Case Rep 2021;24:101218.

125. Fardeau C, Lee CP, Merle-Béral H, Cassoux N, Bodaghi B, Davi F, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non- Hodgkin primary intraocular lymphoma. Am J Ophthalmol 2009;147:886–894.

126. Egawa M, Mitamura Y, Hayashi Y, Naito T. Spectraldomain optical coherence tomographic and fundus autofluorescence findings in eyes with primary intraocular lymphoma. Clin Ophthalmol 2014;8:335–341.

127. Komatsu K, Sakai T, Kaburaki T, Tsuji H, Tsuneoka H. Atypical presentation of primary intraocular lymphoma. BMC Ophthalmol 2016;16:171.

128. Venkatesh R, Gurav P, Abhishek Dave P, Gandhi A. Capillary Dropout: A novel fluorescein angiography finding in primary vitreoretinal lymphoma. Ocul Oncol Pathol 2017;3:324–327.

129. Fardeau C, Lee CP, Merle-Béral H, Cassoux N, Bodaghi B, Davi F, et al. Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non- Hodgkin primary intraocular lymphoma. Am J Ophthalmol 2009;147:886–894, 94.e1.

130. Wang Z, Yang W, Li D, Chen W, Zhao Q, Li Y, et al. Ultrasonographic features of intraocular lymphoma. Chin J Ultrason 2019;28:251–255.

131. Gao S, Zhou Y, Jin X, Lin Z, Zhong Y, Shen X. Primary vitreoretinal natural killer/T-cell lymphoma with breast involvement: A case report and review of the literature. Surv Ophthalmol 2019;64:225–232.

132. Gu J, Chen Q, Zhang P, Zhang T, Zhou X, Zhang K, et al. Characteristics of vitreoretinal lymphoma in B-scan ultrasonography: A case-control study. Ophthalmol Retina 2024;8:264–269.

133. Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina 2011;31:435–440.

134. Lai J, Chen K, Shi HM, Zhuang L, Zhou X, Xiao JJ, et al. B-scan ultrasound and cytology of the vitreous in primary central nervous system lymphoma with vitreoretinal involvement. Int J Ophthalmol 2019;12:1001–1007.

135. Guan W, Zhang Y, Zhang X, Peng X. In vivo confocal microscopy of keratic precipitates in vitreoretinal lymphoma. Ocul Immunol Inflamm 2024;32:919–924.

136. Mahendradas P, Srinivasan T, Kawali A, Venkatesh R, Hazarika D, Patil S, et al. Floral pattern of keratic precipitates in vitreoretinal lymphoma on in vivo confocal microscopy. Ocul Immunol Inflamm 2021;29:500–506.

137. Marchese A, Di Biase C, Cicinelli MV, Menean M, Ferrari G, Bandello F, et al. Anterior segment involvement in vitreoretinal lymphoma: Clinical manifestations, molecular findings and in vivo confocal microscopy. Br J Ophthalmol 2024;108:1168–1171.

138. Zhang P, Tian J, Gao L. Intraocular lymphoma masquerading as recurrent iridocyclitis: Findings based on in vivo confocal microscopy. Ocul Immunol Inflamm 2018;26:362–364.

139. Gozzi F, Bertolini M, Gentile P, Verzellesi L, Trojani V, De Simone L, et al. Artificial intelligence-assisted processing of anterior segment OCT images in the diagnosis of vitreoretinal lymphoma. Diagnostics 2023;13:2451.

140. Diaconita V, Rihani H, Mares V, Nehemy MB, Bakri SJ, Pulido JS. The use of anterior segment optical coherence tomography (ASOCT) in demonstrating recurrence of vitreoretinal lymphoma (VRL) in the anterior vitreous. Int J Retina Vitreous 2019;5:19.

141. Makita J, Yoshikawa Y, Kanno J, Igawa Y, Kumagai T, Takano S, et al. Electroretinographic and optical coherence tomographic evaluations of eyes with vitreoretinal lymphoma. J Clin Med 2023;12:3957.

142. Maruyama K, Iwahashi C, Hashida N, Ohguro N, Nishida K. Relationship between vitreoretinal lymphoma and the site of lymphoma development in the central nervous system. Jpn J Ophthalmol 2022;66:142–150.

143. Giuffrè C, Cicinelli MV, Marchese A, Modorati GM, Brambati M, Ferreri AJ, et al. Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center. Ocul Immunol Inflamm 2021;29:472–478.

144. Silverman RF, Abramson DH, Canestraro J, Grommes C, Francis JH. Vitreoretinal lymphoma: The importance of cerebral spinal fluid evaluation at initial diagnosis. Br J Ophthalmol 2025;109:504–509.

145. Pulido JS, Johnston PB, Nowakowski GS, Castellino A, Raja H. The diagnosis and treatment of primary vitreoretinal lymphoma: A review. Int J Retina Vitreous 2018;4:1–11.

146. Menean M, Giuffrè C, Cicinelli MV, Marchese A, Modorati G, Bandello F, et al. A comprehensive overview of diagnosis, imaging and treatment of vitreoretinal lymphoma. Eur J Ophthalmol 2024;34:931–940.

147. Motomura Y, Yoshifuji K, Tachibana T, Takase H, Arai A, Tanaka K, et al. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma. Br J Haematol 2024;204:1279–1287.

148. Dalvin LA, Pulido JS, Shields CL, Marchese A, Miserocchi E, Frenkel S, et al. Vitreoretinal lymphoma: Central nervous system lymphoma risk with unilateral or bilateral ocular tumour. A multicentre collaboration. Eye 2023;37:54–61.

149. van Rooij JL, Tokarska KA, Ten Dam-van Loon NH, Wessels PH, Seute T, Minnema MC, et al. Central nervous system progression in primary vitreoretinal lymphoma with bilateral and unilateral involvement: A systematic review and meta-analysis. Cancers 2022;14:2967.

150. Kim JY, Kim JJ, Kim RY, Kim M, Park YG, Park YH. Factors related to central nervous system involvement of primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol 2024;262:2421–2429.

151. Liu S, Jiang T, Gu J, Zhou X, Chen W, Ping B, et al. Prognosis, risk factors, and clinical features of intraocular recurrence in primary vitreoretinal lymphoma. Ophthalmol Retina 2024;8:317–324.

152. Yoshifuji K, Sadato D, Toya T, Motomura Y, Hirama C, Takase H, et al. Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma. Haematologica 2024;109:3641–3649.

153. Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma. Br J Haematol 2016;173:680–692.

154. de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, et al. Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma. Am J Hematol 2019;94:455–460.

155. Stefanovic A, Davis J, Murray T, Markoe A, Lossos IS. Treatment of isolated primary intraocular lymphoma with high-dose methotrexate-based chemotherapy and binocular radiation therapy: A single-institution experience. Br J Haematol 2010;151:103–106.

156. Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008;71:1355–1360.

157. Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. Transl Vis Sci Technol 2012;1:1.

158. Hashida N, Nakai K, Saitoh N, Nishida K. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol 2014;252:687–693.

159. Ostrovsky M, Sela TC, Habot-Wilner Z. Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: A systematic review and metaanalysis. Clin Exp Ophthalmol 2024;53:84–99.

160. Giuffrè C, Cicinelli MV, Marchese A, Modorati GM, Brambati M, Ferreri AJ, et al. Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center. Ocul Immunol Inflamm 2021;29:472–478.

161. Kvopka M, Lake SR, Smith JR. Intraocular chemotherapy for vitreoretinal lymphoma: A review. Clin Exp Ophthalmol 2020;48:240–248.

162. Zhou X, Zhou X, Shi H, Lai J, Wang Q, Li Y, et al. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients. BMC Ophthalmol 2020;20:189.

163. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al.; International Extranodal Lymphoma Study Group (IELSG). Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016;3:e217–e227.

164. Calimeri T, Steffanoni S, Gagliardi F, Chiara A, Ferreri AJ. How we treat primary central nervous system lymphoma. ESMO Open 2021;6:100213.

165. Holdhoff M, Mrugala MM, Grommes C, Kaley TJ, Swinnen LJ, Perez-Heydrich C, et al. Challenges in the treatment of newly diagnosed and recurrent primary central nervous system lymphoma. J Natl Compr Canc Netw 2020;18:1571–1578.

166. Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Moluçon-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: A multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA). Ann Oncol 2019;30:621–628.

167. Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II ‘proof-of-concept’ iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer 2019;117:121–130.

168. Baron M, Belin L, Cassoux N, Fardeau C, Blaizeau M, Soussain C, et al. Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood 2020;135:1811–1815.

169. Gao J, Peng X, Wang L. Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: A systematic review and meta-analysis. BMC Ophthalmol 2023;23:477.

170. Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: A 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol 2013;131:50–55.

171. Dalvin LA, Lim LS, Ancona-Lezama D, Mazloumi M, Chang M, Porcu P, et al. Clinical features predictive of survival in patients with vitreoretinal lymphoma: Analysis of 70 patients at a single ocular oncology center. Asia Pac J Ophthalmol 2020;9:110–116.

172. Dalvin LA, Lim LS, Ancona-Lezama D, Mazloumi M, Chang M, Mashayekhi A, et al. Tumor control and visual acuity outcomes in vitreoretinal lymphoma with and without sub-retinal pigment epithelium infiltration: Analysis of 125 eyes of 70 patients at a single ocular oncology center. Ophthalmol Retina 2019;3:998–1005.

173. Kim M, Suh H, Park YG, Park YH. Clinical features predictive of vision loss in patients with vitreoretinal lymphoma: A single tertiary center experience. Sci Rep 2023;13:4478.

174. Cho BJ, Kim DY, Park UC, Lee JY, Yoon YH, Yu HG. Clinical features and treatment outcomes of vitreoretinal lymphoma according to its association with CNS lymphoma. Ocul Immunol Inflamm 2018;26:365–371.

175. Takeda A, Hasegawa E, Nakao S, Ishikawa K, Murakami Y, Hisatomi T, et al. Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma. Sci Rep 2020;10:15715.

176. Tsubota K, Usui Y, Goto H. Identification of prognostic markers in patients with primary vitreoretinal lymphoma by clustering analysis using clinical data. J Clin Med 2020;9:2298.

177. Ferreri AJ, Zucca E, Armitage J, Cavalli F, Batchelor TT. Ten years of international primary CNS lymphoma collaborative group studies. J Clin Oncol 2013;31:3444– 3445.

178. Aronow ME, Portell CA, Sweetenham JW, Singh AD. Uveal lymphoma: Clinical features, diagnostic studies, treatment selection, and outcomes. Ophthalmology 2014;121:334– 341.

179. Tang LJ, Gu CL, Zhang P. Intraocular lymphoma. Int J Ophthalmol 2017;10:1301–1307.

180. Davis JL. Intraocular lymphoma: A clinical perspective. Eye 2013;27:153–162.

181. Mashayekhi A, Shukla SY, Shields JA, Shields CL. Choroidal lymphoma: Clinical features and association with systemic lymphoma. Ophthalmology 2014;121:342– 351.

182. Zhang L, Zhang T, Xu G, Zhang C, Qian J, Chang Q, et al. Multipurpose ultrasonographic characteristics of primary uveal MALT lymphoma. Graefes Arch Clin Exp Ophthalmol 2023;261:2383–2394.

183. Zhang L, Zhang T, Xu G, Zhang C, Qian J, Chang Q, et al. Multipurpose ultrasonographic characteristics of primary uveal MALT lymphoma. Graefes Arch Clin Exp Ophthalmol 2023;261:2383–2394.

184. Shields CL, Arepalli S, Pellegrini M, Mashayekhi A, Shields JA. Choroidal lymphoma shows calm, rippled, or undulating topography on enhanced depth imaging optical coherence tomography in 14 eyes. Retina 2014;34:1347–1353.

185. Pellegrini M, Preziosa C, Yaghy A, Ruben M, Invernizzi A, Fung AT, et al. Choroidal lymphoma: Diagnostic value of combined indocyanine green angiography and optical coherence tomography. Ocul Immunol Inflamm 2023;31:263–270.

186. McKay KM, Nishath T, Grieco VS, Stacey AW. Diagnostic confirmation of choroidal lymphoma by anterior chamber paracentesis and aqueous fluid flow cytometry. Ocul Immunol Inflamm 2024;32:1091–1096.

187. Mastropasqua R, Thaung C, Pavesio C, Lightman S, Westcott M, Okhravi N, et al. The Role of Chorioretinal Biopsy in the Diagnosis of Intraocular Lymphoma. Am J Ophthalmol 2015;160:1127–1132.e1.

188. Hernández-Pons A, Gómez-Beltrán E, Fernández-Zarzoso M, Albert-Fort M, Martínez-Costa L. Choroidal lymphoma diagnosed by polymerase chain reaction-based clonality assessment. Eur J Ophthalmol 2021;31:NP97–NP101.

189. Cho J. Basic immunohistochemistry for lymphoma diagnosis. Blood Res 2022;57:55–61.

190. Di Y, Ye J, Han R, Li M, Zhang B. Case report: Ocular manifestations and treatments of ciliary body involvement by lymphoma. Front Oncol 2021;11:718759.

191. Di Y, Ye JJ, Zhang BL. Systemic diffuse large B-cell lymphoma with bilateral ciliary body involvement. Chin Med J 2020;133:109–110.

192. Bian A, Min H, Dai R, Zhao C, Zhang Y, Liang A, et al. Ring lymphoma: Highly indicative ultrasound biomicroscopy findings of ciliary body lymphoma. Graefes Arch Clin Exp Ophthalmol 2021;259:2005–2008.

193. Conway RM, Chew T, Golchet P, Desai K, Lin S, O’Brien J. Ultrasound biomicroscopy: Role in diagnosis and management in 130 consecutive patients evaluated for anterior segment tumours. Br J Ophthalmol 2005;89:950–955.

194. Mashayekhi A, Shields CL, Shields JA. Iris involvement by lymphoma: A review of 13 cases. Clin Exp Ophthalmol 2013;41:19–26.

195. Lobo A, Larkin G, Clark BJ, Towler HM, Lightman S. Pseudo-hypopyon as the presenting feature in B-cell and T-cell intraocular lymphoma. Clin Exp Ophthalmol 2003;31:155–158.

196. Doro D, Parrozzani R, Midena E. Ultrasound biomicroscopy examination of anterior uveal tumors: information on location and size only? Acta Clin Croat 2012;51:37–44.

197. Gauthier AC, Nguyen A, Munday WR, Xu ML, Materin MA. Anterior chamber non-Hodgkin lymphoma of the iris masquerading as uveitis-glaucoma-hyphema syndrome. Ocul Oncol Pathol 2016;2:230–233.

198. Camp DA, Yadav P, Dalvin LA, Shields CL. Glaucoma secondary to intraocular tumors: Mechanisms and management. Curr Opin Ophthalmol 2019;30:71–81.

199. Llorenç V, Fuster C, Alba-Linero C, Moll-Udina A, Serrano A, Solé M, et al. Clinical features of primary and systemic metastatic intraocular lymphomas in Spanish patients. J Ophthalmol 2019;2019:6327041.

200. Mashayekhi A, Hasanreisoglu M, Shields CL, Shields JA. External beam radiation for choroidal lymphoma: Efficacy and complications. Retina 2016;36:2006–2012.

201. Kakkassery V, Coupland SE, Heindl LM. Iris lymphoma- A systematic guide for diagnosis and treatment. Surv Ophthalmol 2021;66:41–53.

202. Llorenç V, Fuster C, Alba-Linero C, Moll-Udina A, Serrano A, Solé M, et al. Clinical features of primary and systemic metastatic intraocular lymphomas in Spanish patients. J Ophthalmol 2019;2019:6327041.

203. Coupland SE, Damato B. Understanding intraocular lymphomas. Clin Exp Ophthalmol 2008;36:564–578.

204. Levy-Clarke GA, Greenman D, Sieving PC, Byrnes G, Shen D, Nussenblatt R, et al. Ophthalmic manifestations, cytology, immunohistochemistry, and molecular analysis of intraocular metastatic T-cell lymphoma: Report of a case and review of the literature. Surv Ophthalmol 2008;53:285–295.

205. Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, et al. Role of systemic highdose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990–2018. Am J Hematol 2019;94:291–298.

206. Valenzuela J, Yeaney GA, Hsi ED, Azzato EM, Peereboom DM, Singh AD. Large B-cell lymphoma of the uvea: Histopathologic variants and clinicopathologic correlation. Surv Ophthalmol 2020;65:361–370.

207. Bendari A, Abdelhafez A, Sham S, Al-Refai R, Yurovitsky A. Intravascular large B-cell lymphoma (IVLBCL): subtle presentation and challenging diagnosis; A case report. Surg Exp Pathol 2024;7:9.

208. Roditi E, Panicker S, Fung AT. Intravascular large B-cell lymphoma of the eye: Literature review and new findings. Asia Pac J Ophthalmol 2024;13:100053.

209. Sánchez-Vicente JL, De Las Morenas-Iglesias J, Franco- Ruedas C, Rueda-Rueda T, Moruno-Rodríguez A, Lechón- Caballero B, et al. Ocular involvement in a patient with intravascular large B-cell lymphoma: A diagnostic challenge. Clinical case report and literature review. Ocul Immunol Inflamm 2024;32:869–876.

210. Lee HB, Pulido JS, Buettner H, Salomão D, Zent CS, Link TP. Intravascular B-cell lymphoma (angiotropic lymphoma) with choroidal involvement. Arch Ophthalmol 2006;124:1357–1359.

211. Liu Z, Zhang Y, Zhu Y, Zhang W. Prognosis of intravascular large B cell lymphoma (IVLBCL): Analysis of 182 patients from global case series. Cancer Manag Res 2020;12:10531–10540.